GSK 626616

Key Product Details

Product Description

GSK 626616 is a potent and selective DYRK inhibitor (IC₅₀ = 0.7 nM for DYRK3, similar potency for DYRK1 and 2). Exhibits ~20-fold selectivity over casein kinase 2 and negligible activity against a panel of 451 kinases screened. Enhances number of CFU-E stimulated by Epo from human marrow. Increases hemoglobin levels in anemic mice. Orally bioavailable.

Product Specifications for GSK 626616

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GSK 626616

The following data is based on the product molecular weight 401.27.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.49 mL	12.46 mL	24.92 mL
5 mM	0.50 mL	2.49 mL	4.98 mL
10 mM	0.25 mL	1.25 mL	2.49 mL
50 mM	0.05 mL	0.25 mL	0.50 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 8 publications citing the usage of this product.

• Wippich Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell 2013 PMID: 23415227
• Rai Kinase-controlled phase transition of membraneless organelles in mitosis. Nature 2018 PMID: 29973724
• Erickson-Miller GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia. Blood

Product Documents for GSK 626616